bioSyntagma, LLC, a precision medicine company, has been awarded a National Science Foundation (NSF) Phase II Small Business Innovation Research (SBIR) grant of $735,139, to continue development of technology that can isolate rare cancer cells from patient biopsies.
In Phase I, the company demonstrated the feasibility of its LightStream FloCellTM technology, which maps the location of diseased cells across a tissue and then isolates those cells for genetic analysis. This creates a digital, interactive, and quantitative map of disease in tissues.
This technology enables bioSyntagma’s Molecular Fingerprint™ (mPrint) Platform that creates comprehensive patient profiles to match patients with relevant therapies and to prevent acquired drug resistance, especially high in cancer patients.
Funding will be used to produce its first beta instruments by implementing the technology into a high-throughput commercial product.
“It will allow us to commercially launch our platform technology for discovery and implementation of precision medicines,” said David Richardson, CEO of bioSyntagma.
It expects to hire additional staff to support development as well as create artificial intelligence algorithms to mine the data produced on these instruments.
